Harbin Gloria Pharmaceuticals Co., Ltd (002437.SZ)
CNY 2.36
(-1.26%)
CNY 2.36
(-1.26%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 275.28 Million CNY | 1387.71% |
| 2022 | 18.5 Million CNY | -93.85% |
| 2021 | 301.95 Million CNY | -67.76% |
| 2020 | 818.85 Million CNY | 86.16% |
| 2019 | -2.23 Billion CNY | -39.34% |
| 2018 | 519.52 Million CNY | 6.33% |
| 2017 | 714 Million CNY | -34.56% |
| 2016 | 1.12 Billion CNY | 10.08% |
| 2015 | 1.05 Billion CNY | 61.41% |
| 2014 | 678.79 Million CNY | 174.04% |
| 2013 | 241.35 Million CNY | 30.84% |
| 2012 | 184.83 Million CNY | 18.87% |
| 2011 | 157.81 Million CNY | -22.49% |
| 2010 | 205.19 Million CNY | 19.57% |
| 2009 | 168.04 Million CNY | 38.62% |
| 2008 | 121.82 Million CNY | 52.7% |
| 2007 | 80.43 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 84.52 Million CNY | 207.42% |
| 2024 Q3 | 69.98 Million CNY | -36.6% |
| 2024 Q2 | 95.89 Million CNY | 14.95% |
| 2023 Q1 | 47.1 Million CNY | 118.37% |
| 2023 Q3 | 234.92 Million CNY | 747.82% |
| 2023 Q4 | -89.39 Million CNY | -138.05% |
| 2023 FY | - CNY | 1387.71% |
| 2023 Q2 | 27.71 Million CNY | -41.18% |
| 2022 Q2 | 43.35 Million CNY | -13.21% |
| 2022 Q1 | 49.95 Million CNY | 359.17% |
| 2022 Q4 | -256.49 Million CNY | -596.59% |
| 2022 Q3 | 51.65 Million CNY | 19.15% |
| 2022 FY | - CNY | -93.85% |
| 2021 Q2 | 136.01 Million CNY | 180.13% |
| 2021 FY | - CNY | -67.76% |
| 2021 Q3 | -8.73 Million CNY | -106.42% |
| 2021 Q1 | 48.55 Million CNY | 149.49% |
| 2021 Q4 | -19.27 Million CNY | -120.77% |
| 2020 Q1 | 807.69 Million CNY | 549.01% |
| 2020 FY | - CNY | 86.16% |
| 2020 Q3 | 33.84 Million CNY | -35.34% |
| 2020 Q4 | -98.1 Million CNY | -389.87% |
| 2020 Q2 | 52.34 Million CNY | -93.52% |
| 2019 FY | - CNY | -39.34% |
| 2019 Q1 | 138.6 Million CNY | 17.29% |
| 2019 Q2 | 214.97 Million CNY | 55.1% |
| 2019 Q3 | 145.1 Million CNY | -32.5% |
| 2019 Q4 | -179.88 Million CNY | -223.97% |
| 2018 Q2 | 236.77 Million CNY | 63.61% |
| 2018 Q3 | 142.94 Million CNY | -39.63% |
| 2018 Q1 | 144.71 Million CNY | 12.7% |
| 2018 Q4 | 118.17 Million CNY | -17.33% |
| 2018 FY | - CNY | 6.33% |
| 2017 Q1 | 181.37 Million CNY | -45.88% |
| 2017 FY | - CNY | -34.56% |
| 2017 Q3 | 127.77 Million CNY | -20.35% |
| 2017 Q4 | 128.4 Million CNY | 0.5% |
| 2017 Q2 | 160.42 Million CNY | -11.55% |
| 2016 Q4 | 335.16 Million CNY | 35.87% |
| 2016 Q2 | 281.64 Million CNY | 42.78% |
| 2016 Q1 | 197.25 Million CNY | -30.52% |
| 2016 FY | - CNY | 10.08% |
| 2016 Q3 | 246.68 Million CNY | -12.41% |
| 2015 FY | - CNY | 61.41% |
| 2015 Q3 | 220.53 Million CNY | -23.99% |
| 2015 Q2 | 290.14 Million CNY | 82.15% |
| 2015 Q1 | 159.29 Million CNY | -29.88% |
| 2015 Q4 | 283.88 Million CNY | 28.73% |
| 2014 Q1 | 74.15 Million CNY | 18.98% |
| 2014 FY | - CNY | 174.04% |
| 2014 Q3 | 106.77 Million CNY | -42.52% |
| 2014 Q2 | 185.75 Million CNY | 150.49% |
| 2014 Q4 | 227.15 Million CNY | 112.75% |
| 2013 Q2 | 51.72 Million CNY | 142.37% |
| 2013 Q3 | 46.91 Million CNY | -9.31% |
| 2013 Q4 | 62.32 Million CNY | 32.85% |
| 2013 FY | - CNY | 30.84% |
| 2013 Q1 | 21.34 Million CNY | -66.63% |
| 2012 Q2 | 60.73 Million CNY | 244.35% |
| 2012 Q4 | 63.96 Million CNY | 256.51% |
| 2012 FY | - CNY | 18.87% |
| 2012 Q1 | 17.63 Million CNY | -63.42% |
| 2012 Q3 | 17.94 Million CNY | -70.46% |
| 2011 Q1 | 18.43 Million CNY | -74.32% |
| 2011 Q2 | 57.02 Million CNY | 209.34% |
| 2011 Q3 | 14.78 Million CNY | -74.08% |
| 2011 Q4 | 48.21 Million CNY | 226.1% |
| 2011 FY | - CNY | -22.49% |
| 2010 Q4 | 71.8 Million CNY | 75.78% |
| 2010 Q2 | 57.98 Million CNY | 211.93% |
| 2010 Q3 | 40.84 Million CNY | -29.56% |
| 2010 FY | - CNY | 19.57% |
| 2010 Q1 | 18.59 Million CNY | -72.9% |
| 2009 Q4 | 68.58 Million CNY | 128.06% |
| 2009 FY | - CNY | 38.62% |
| 2009 Q2 | 45.99 Million CNY | 224.8% |
| 2009 Q1 | 14.16 Million CNY | 0.0% |
| 2009 Q3 | 30.07 Million CNY | -34.61% |
| 2008 FY | - CNY | 52.7% |
| 2007 FY | - CNY | 0.0% |